Size 1) clinical trials

A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults with Seizures Associated with Tuberous Sclerosis Complex

This study is looking at a new medicine called Basimglurant for children, teenagers, and young adults with seizures caused by Tuberous Sclerosis Complex. It wants to see if the drug helps reduce seizures and if it's safe when added to their usual seizure medication.